Second-line treatment of metastatic gastric cancer: Current options and future directions

doi:10.3748/wjg.v21.i41.11621

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 41

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12429)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

781

WORD

403

HTML

7234

Tables (1-3)

652

Sum=9070

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1306

Download

2054

Sum=3360

Nov 7, 2015 (publication date) through Mar 2, 2026

Times Cited of This Article

Times Cited (34)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Topic Highlight

World J Gastroenterol. Nov 7, 2015; 21(41): 11621-11635
Published online Nov 7, 2015. doi: 10.3748/wjg.v21.i41.11621

Second-line treatment of metastatic gastric cancer: Current options and future directions

Dheepak Kanagavel, Mikhail Fedyanin, Alexey Tryakin, Sergei Tjulandin

Dheepak Kanagavel, Mikhail Fedyanin, Alexey Tryakin, Sergei Tjulandin, Department of Clinical Pharmacology and Chemotherapy, N. N. Blokhin Russian Cancer Research Center, Moscow 115478, Russia

Author contributions: Kanagavel D, Fedyanin M, Tryakin A and Tjulandin S contributed equally to this work; Tryakin A and Tjulandin S designed research; Kanagavel D and Fedyanin M performed research and analyzed data; and Kanagavel D, Fedyanin M, Tryakin A and Tjulandin S wrote the paper.

Conflict-of-interest statement: The authors have no conflict of interest to report.

Correspondence to: Sergei Tjulandin, Professor, Department of Clinical Pharmacology and Chemotherapy, N. N. Blokhin Russian Cancer Research Center, Kashirskoe Shosse 24, Moscow 115478, Russia. stjulandin@mail.ru

Telephone: +7-499-3249844 Fax: +7-499-3249834

Received: April 28, 2015
Peer-review started: May 5, 2015
First decision: July 13, 2015
Revised: August 14, 2015
Accepted: September 30, 2015
Article in press: September 30, 2015
Published online: November 7, 2015
Processing time: 189 Days and 15.6 Hours

Core Tip

Core tip: This systematic review has analyzed the currently available treatment options with chemotherapy and targeted agents in the second-line treatment of metastatic gastric cancer. In addition, this review has discussed the future directions of research and the prognostic factors that influence patient survival in those receiving second-line therapy for metastatic gastric cancer.